Qlaira 3 mg FC tablets
PDF Leaflet Revision Date: 30 September 2011
Clinical Summary
Quick overview from the medicine insert
Indication
Oral contraception.
Dosage (summary)
Start on day 1 of menstrual cycle; follow specific guidelines for switching from other contraceptives.
Special Populations
- Not for use in women under 18 years
Pregnancy & Breastfeeding
Contraindicated in pregnancy; may reduce breast milk quantity and change composition during lactation.
Key Drug Interactions
- CYP3A4 inducers (e.g., rifampicin)
- CYP3A4 inhibitors (e.g., ketoconazole)
- Antibiotics (e.g., penicillins)
Contraindications
- History of thromboembolic events
- Migraine with focal neurological symptoms
- Severe diabetes with vascular involvement
- Liver disease
- Known or suspected pregnancy
Common side effects
- Headache
- Breast pain
- Nausea
- Mood changes
- Acne
Counselling Points
- Use barrier contraception if pills are missed or during gastrointestinal disturbances
- Regular medical check-ups recommended
- Does not protect against STIs
Serious warnings
- Increased risk of thromboembolic events
- Monitor for hypertension
- Potential for cervical cancer risk with long-term use
Important Disclaimer
The Qlaira 3 mg FC tablets professional information leaflet below is the property of Bayer and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
